
1. nat commun. 2019 sep 24;10(1):4328. doi: 10.1038/s41467-019-11980-6.

potent antibody lineage malaria transmission elicited human
vaccination pfs25.

mcleod b(1)(2), miura k(3), scally sw(1), bosch a(1), nguyen n(4), shin h(4), kim
d(4), volkmuth w(4), r√§misch s(5), chichester ja(6), streatfield s(7), woods
c(8), schief wr(5), emerling d(4), king cr(8), julien jp(9)(10)(11).

author information: 
(1)program molecular medicine, hospital sick children research
institute, 686 bay street, toronto, on, m5g 0a4, canada.
(2)department biochemistry, university toronto, 1 king's college circle,
toronto, on, m5s 1a8, canada.
(3)laboratory malaria vector research, national institute allergy and
infectious diseases, national institutes health, 12735 twinbrook parkway,
rockville, md, 20852, usa.
(4)atreca, 500 saginaw drive, redwood city, ca, 94063-4750, usa.
(5)department immunology microbial science, scripps research
institute, la jolla, ca, 92037, usa.
(6)gene therapy program & orphan disease center, perelman school medicine, the
university pennsylvania, philadelphia, pa, 19104, usa.
(7)fraunhofer usa center molecular biotechnology cmb, 9 innovation way,
newark, de, 19711, usa.
(8)path's malaria vaccine initiative, 455 massachusetts avenue nw suite 1000,
washington, dc, 20001, usa.
(9)program molecular medicine, hospital sick children research
institute, 686 bay street, toronto, on, m5g 0a4, canada.
jean-philippe.julien@sickkids.ca.
(10)department biochemistry, university toronto, 1 king's college circle,
toronto, on, m5s 1a8, canada. jean-philippe.julien@sickkids.ca.
(11)department immunology, university toronto, 1 king's college circle,
toronto, on, m5s 1a8, canada. jean-philippe.julien@sickkids.ca.

transmission-blocking vaccines potential key contributors to
malaria elimination. vaccines elicit antibodies inhibit parasites
during development anopheles mosquitoes, thus breaking cycle of
transmission. date, characterization humoral responses plasmodium
falciparum transmission-blocking vaccine candidate pfs25 largely been
conducted pre-clinical models. here, present molecular analyses human
antibody responses generated clinical trial evaluating pfs25 vaccination.
from collection monoclonal antibodies transmission-blocking activity,
we identify potent transmission-blocking antibody yet described 
pfs25; 2544. interactions 2544 three antibodies pfs25 are
analyzed crystallography understand structural requirements elicitation
of human transmission-blocking responses. analyses provide insights into
pfs25 immunogenicity epitope potency, detail affinity maturation
pathway potent transmission-blocking antibody humans. findings can
be employed guide design improved malaria transmission-blocking
vaccines.

doi: 10.1038/s41467-019-11980-6 
pmcid: pmc6760140
pmid: 31551421  [indexed medline]

